VI,
I'm sure you're right about many of them, however I'm not certain that people like Iron Mike aren't frustrated longs. I've seen it in IMGN and others where people who still believe in the technology become frustrated with management. They become critical of the company, yet they're still long the stock. When the company moves up dramatically they may turn into cheerleaders again, and have a healthy profit in their accounts.
Frankly, I respect management that keeps out of the day to day share price moves and doesn't try to hype every minor issue they could, like the filing or issuance of patents. I've seen companies that report every such issue, those like CVM who keep searching for a disease that works with their cure. There seem to always be people who'll invest in the new claims such companies make without looking at their history of failures in other diseases, all treated with the very same drug, it's all they have.
I believe that management here has been telling us all along what they're doing, but they're not providing significant information on how long it will take. I think most CEO's believe that things should happen faster than they do, they're clearly optimists in life. I think the show "Undercover Boss" generally shows how CEO's and others learn a good lesson when they try to do the jobs their employees face daily. LP is realist enough to recognize what must be done, but she's also realistic enough to know that she cannot take on all her critics. The way she wins is by doing what needs to be done, starting with gaining approvals, and building the company after that. She knows we'll not be labeled Tumor Agnostic from day one, but if by the end of this decade many are using DCVax-L in that manner, even if no labeling has yet been achieved, this will be one of the biggest gainers in the decade if the company remains independent. If we're bought out, of course we'll be wealthy, and LP will probably be the wealthiest among us, but I'm really not certain that it's her goal.
Gary
News 
Market Data 
Discover 
